Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2309-2318

  Dowlati, A ^a   Hoppel, C L ^a   Ingalls, S T ^a   Majka, S ^a   Li, X ^a   Sedransk, N ^a   Spiro, T ^a   Gerson, S L ^a   Ivy, P ^a   Remick, S C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; ONDANSETRON; PROCHLORPERAZINE; REBECCAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOXICITY; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0035871186     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2309     Document Type: Article

References (16)

1. Two synthetic approaches to rebeccamycin
2. Isolation and structure of rebeccamycin: A new antitumor antibiotic from Nocardia aerocolonigenes
3. Water soluble derivatives of rebeccamycin
4. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group
5. Production and biological activity of rebeccamycin, a novel antitumor agent
6. Fluorescence polarization studies of the binding of BMS 181176 to DNA
7. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin
8. Structure-activity relationships in a series of substituted indolocarbazoles: Topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties
9. A phase I clinical and pharmacokinetic study of the rebeccamycin analog NSC 655649 in patients with advanced cancer
10. Phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC 655649)
11. An information criterion (AIC)
12. Secondary leukemias induced by topoisomerase-targeted drugs
13. LC/MS identification of a rebeccamycin analog metabolite
14. Cytochrome P-450 metabolism of the rebeccamycin analog NSC 655649